Diagnostic and prognostic values of contrast‑enhanced ultrasound combined with diffusion‑weighted magnetic resonance imaging in different subtypes of breast cancer.

The study addresses a clinically relevant question — whether combining CEUS and DW-MRI improves breast cancer subtype classification — but the advance is incremental and confirmatory. The prognostic findings (HER2-positive subtype has worst outcomes) were well-established by 2017 and do not represent novel discoveries.

The study design is appropriate for a diagnostic accuracy comparison, with IHC as the reference standard and both imaging modalities performed preoperatively. However, the paper reports only overall accuracy percentages without sensitivity, specificity, PPV, NPV, or AUC — a fundamental omission for a diagnostic accuracy study that substantially limits interpretability of the central claims. No blinding of imaging readers to IHC results is described.

The paper follows a conventional structure with logical flow from methods through results to discussion. However, numerical discrepancies between the Abstract (93.10% combined accuracy) and Results/Table IV (90.09%) on the primary outcome create genuine confusion about which figures are authoritative, and '[Author] et al.' placeholders in the Discussion indicate incomplete manuscript preparation.

The Introduction provides a reasonable overview of CEUS and DW-MRI in breast cancer, and the Discussion cites relevant prior work. However, the literature engagement is formulaic and supportive rather than critical, and the limitations section consists of a single sentence acknowledging sample size without addressing the absence of diagnostic accuracy metrics, observer bias, or single-centre constraints.

The paper addresses a recognized clinical need for improved preoperative breast cancer subtype stratification to guide treatment planning. The target population and clinical context are identifiable but the specific decision pathway where imaging-predicted subtypes would supplement IHC is not articulated.

The study represents retrospective single-centre proof-of-concept using clinically available imaging modalities, but provides no diagnostic algorithm, decision thresholds, or implementation guidance for combining CEUS and DW-MRI findings in practice. No external validation or prospective workflow integration is demonstrated.

Generalisability is limited by single-centre design at a Chinese tertiary hospital with a relatively young cohort (mean age 44.3±7.2 years). No multi-site validation, sensitivity analyses for imaging thresholds, or discussion of scanner/protocol variability is provided.

The paper connects to an active evidence base on multimodal breast imaging and molecular subtype characterisation, adding a data point to cumulative evidence. However, it does not fill a clearly identified gap in prior synthesis or guideline development, and the '[Author] et al.' citation anomalies limit verification of literature engagement.